A Study of Women With an Early Diagnosis of Breast Cancer, Taking Celecoxib Between the Biopsy and Lumpectomy/Mastectomy

Exclusion Criteria

• •no hormone replacement therapy within the 90 days prior to biopsy
• •if on prevention tamoxifen or raloxifene, must have begun administration at least six weeks prior to initial biopsy and continue through reexcision
• •no evidence of metastatic malignancy of any kind
• •no history of asthma, allergy ASA, NSAIDS, celecoxib or other COX-2 inhibitors for a chronic non-oncological condition with the excision of low dose ASA (160 mg daily) during 4 weeks prior to biopsy and for the duration of the study.
• •no celecoxib or rofecoxib use within one month of biopsy
• •no history of gastrointestinal ulcer or ulcerative colitis requiring treatment
• •no current anticoagulants
• •no neoadjuvant antihormone or chemotherapy as treatment following biopsy prior to study entry or concurrently with participation on study
• •no aromatase inhibitor in the six months prior to participation
• •no concomitant lithium
• •no known significant bleeding disorder